ホーム / コンテンツ / Webinar / The Scary Future of Rare Disease Management

The Scary Future of Rare Disease Management

Live webinar

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug interventions that do not meaningfully benefit their covered lives. Rare disease therapies, often viewed as attractive areas for pharmaceutical & biotech manufacturers, represent some of the most expensive interventions available today given inherently limited competition. Yet, as more manufacturers enter these spaces, the question for payers is how to ensure they are paying for the right therapy to allow rare disease patients to live fulfilling, healthy lives. How will payers tackle scary questions surrounding the cost of rare disease treatments? What is the impact of increasing competition in these spaces? What does this mean for manufacturers already playing in this space?

Join the Certara Evidence & Access team for a presentation on original research exploring these topics – and how you can be prepared for both the tricks – and the treats – of the scary future of rare disease management.

Register

Thank you for registering!

Speakers
Maximilian Vargas
Sr. Director, US Access Strategy
Maximilian Vargas, PhD MBA, is a Senior Director, US Access Strategy and Account Management within Certara’s Evidence and Access Group since 2012. He brings both scientific training and experience in healthcare product development that are important for evidence-based value and access strategies for pipeline and marketed products.
Wah Yan
Director, Evidence and Access
トップに戻る
Powered by Translations.com GlobalLink OneLink Software